Dupilumab, marketed as Dupixent, is already established in the treatment of various allergic and inflammatory conditions, including asthma and atopic dermatitis. The current Phase 2 trial aims to expand its indications to eosinophilic gastritis (EoG) and eosinophilic duodenitis (EoD), which are niche but underserved markets. Given the increasing prevalence of eosinophilic gastrointestinal diseases, successful outcomes could position Regeneron and its collaborator Sanofi favorably against competitors in the immunotherapy space. The trial's focus on both efficacy and safety, along with the potential for a broader therapeutic application, enhances its commercial viability. However, the exclusion of patients with EoD only may limit the addressable patient population.